Disease × Country Feasibility Report
Disease-specific feasibility intelligence for sponsors and CROs — competitive sponsor landscape, ranked site shortlists, pipeline depth and operational timelines, scoped to a single therapeutic area in a single country.
Q2 2026Generated 7 October 2026EU Clinical Research
Sponsor competitive map
Every active sponsor in the indication, ranked by trial volume with per-sponsor site networks.
Ranked site shortlist
Up to 40 research sites scored on trial volume, sponsor diversity, Phase III exposure and recruiting status.
IMP & CRO landscape
All tested investigational substances, regulatory-to-start timelines, and the operational vendor ecosystem.
Report overview
What this report includes
Each Market Entry Report maps the complete clinical-trial landscape for a single disease in a single country. It is built for two decisions: strategic — should we run a trial here, with whom, on what timeline; and operational — which sites to prioritise for outreach, where competitive pressure sits, which vendors are already active.
- check_circle Map every sponsor active in your target indication
- check_circle Identify Phase III-capable sites with multi-sponsor trust
- check_circle Spot competitive concentration and Top-N market share
- check_circle Find workhorse sites simultaneously selected by multiple top sponsors
- check_circle Benchmark regulatory-to-start timelines (Decision → Start)
- check_circle Surface investigational compounds defining the competitive frontier
- check_circle Get city-level geographic distribution for site outreach planning
- check_circle Compare industry vs academic sponsor split for partnership scouting
- check_circle Locate the CRO and service-vendor ecosystem already operating
- check_circle Reproduce the analysis — full methodology, scope filter, KPI glossary
Report contents
- 01 Executive Summary
- 02 Scope & Definitions
- 03 Market Overview
- 04 Sponsor Ranking
- 05 Sponsor Sites — Per-Sponsor Networks
- 06 Trial Status & Geographic Distribution
- 07 Detailed Analysis — Concentration & Pipeline Stages
- 08 Enrollment, Duration & Activity Profile
- 09 Research Sites & Investigators
- 10 Site Shortlist — Recommended Centers
- 11 Site Shortlist — Backup Candidates
- 12 Medications & Regulatory Timeline
- 13 CRO & Service Provider Landscape
- 14 Extended Sponsor Directory
- 15 Methodology & Definitions
Example: Spain — Neoplasms malignant site unspecified NEC
A preview of selected insights from one of our Market Entry Reports.
Market Entry Report · Preview
Neoplasms malignant site unspecified NEC
Spain — clinical trial landscape, sponsors, sites & pipeline
EU Clinical Research
May 2026
Market Snapshot
Total Trials
277
In-scope clinical studies
Active Sponsors
130
Unique organisations
Currently Recruiting
38.6%
107 trials enrolling
Research Cities
56
Lead: Madrid (225 trials)
Market leadership: Merck Sharp & Dohme LLC leads with 13 trials (4.7% market share). Top 5 sponsors control 18.1% of all activity — moderately competitive market with room for new entrants.
Sponsor Landscape
Top Sponsors by Trial Volume
Leading commercial sponsors in Spain.
Site Intelligence
Top Research Sites
Ranked by Experience Score: trials × sponsor diversity × Phase III exposure × active recruiting.
| # | Site | City | Trials | Sponsors | Score |
|---|---|---|---|---|---|
| 1 | Hospital Universitario HM Sanchinarro | Madrid | 81 | 52 | ★★★★★ |
| 2 | Hospital Universitario 12 de Octubre | Madrid | 62 | 45 | ★★★★★ |
| 3 | Hospital Clinic de Barcelona | Barcelona | 32 | 24 | ★★★★★ |
| 4 | Hospital Universitario Ramón y Cajal | Madrid | 24 | 20 | ★★★★★ |
Pipeline & Compounds
Development Stages & Tested Substances
Top Phases (of 14)
Top IMPs (of 178)
Get the complete Market Entry Report
All 130 sponsors with site networks, the full 40-site shortlist with Experience Scores, complete IMP & CRO landscape, regulatory timelines, and competitive analysis.
lock_open Unlock full reportWhy this report matters
How this report supports decision-making
The report provides a consistent, data-driven view of national clinical trial environments, supporting strategic planning and market evaluation.
Sponsors — benchmark your competitive position. See every active sponsor in the indication, Top-5 and Top-10 share, industry vs academic split, and the per-sponsor site networks behind each rank.
CROs — evaluate site feasibility fast. The Site Shortlist ranks up to 40 sites by Experience Score, with trial volume, sponsor diversity, Phase III exposure and recruiting status all in one table.
Business Development — find white space and partnership angles. Workhorse-site analysis surfaces multi-sponsor trust signals; the IMP list reveals the competitive compound frontier; CRO landscape maps existing operational alliances.
Looking for more detailed insights?
The reports shown above are just examples available for immediate download. For your specific disease and country combination, contact us — we have a much broader catalogue and can prepare the exact scope you need.